Corporate Science Grants

American Society for Pharmacology and Experimental Therapeutics Division for Drug Metabolism Early Career Achievement Award

The ASPET Division for Drug Metabolism Early Career Achievement Award has been established to recognize excellent original research by early career investigators in the area of drug metabolism and disposition.

The award is presented biennially in odd-numbered years. The award consists of $1,000, a plaque, and complimentary registration plus travel expenses (to a maximum of $1,000) for the winner to attend the award ceremony at the annual meeting. The awardee will deliver a lecture at the annual meeting describing their relevant research accomplishments. The awardee will be invited to publish a review article on the subject matter of the award lecture in Drug Metabolism and Disposition.

Nominees for this award must have a doctoral degree (e.g. Ph.D., M.D., Pharm. D., D.V.M.) and must be within 15 years of having received their final degree, as of December 31 of the year of the award. There are no restrictions on institutional affiliation and a candidate need not be a member of ASPET. There is a requirement for two nominators, although more are acceptable. Nominators must be members of ASPET. An individual cannot nominate more than one candidate per award cycle.

Candidates who have made their research contributions in any sector (e.g. academia, industry, government) of the drug metabolism community may be nominated for the award. The primary criterion for the award is the level of excellence and originality of the research conducted by the candidate in the field of drug metabolism and disposition. Independence of thought, originality of approach, clarity of communication, and the impact of the work on the drug metabolism field are important considerations. Candidates shall not be judged in comparison with the work of more experienced investigators. Selection will be made by the Executive Committee of the Division for Drug Metabolism.

Nominations shall consist of the following components:

Two or more letters of nomination and support.
The five most significant published papers authored by the candidate. A detailed examination of these publications will form a primary basis for evaluation.
The candidate’s curriculum vitae and publication list.

All materials must be submitted as e-mail attachments in pdf format. Submit e-mail attachments to jane.nelson@aspet.org. Nominations for this award must be received no later than September 15, 2010.

ASPET Inquiries
9650 Rockville Pike
Bethesda, MD
20814-3995

Phone: (301) 634-7135
Fax: (301) 634-7061
Email: info@aspet.org

American Association for Cancer Research Team Science Award

Unparalleled opportunities now exist to detect, diagnose, prevent, and more effectively treat cancer due to the sequencing of the human genome, progress in systems biology, and the advancement of computer science and other technologies. Capitalizing on these opportunities often depends on the participation of researchers in specialties that include, but are not limited to, chemistry, physics, engineering, computational science, and nanotechnology. The integration of such specialties into cancer and biomedical research form the bases of interdisciplinary scientific teams.

This Award has been established by the American Association for Cancer Research and Eli Lilly and Company to acknowledge and catalyze the growing importance of interdisciplinary teams to the understanding of cancer and/or the translation of research discoveries into clinical cancer applications. Proactive interaction between academic and industry researchers is particularly crucial to continue progress and accelerate drug development.

In addition, through the presentation of this Award, the AACR and Eli Lilly seek to effect change within the traditional cancer research culture by recognizing those institutions that value and foster interdisciplinary team science. These institutions will have demonstrated their support of a team science environment by creating mechanisms to enhance the required infrastructure, such as through pilot funding, technology transfer offices, shared resources, etc., and by presenting awards, honors, appointments, and promotions to those who participate in interdisciplinary teams.

The AACR Team Science Award will recognize an outstanding interdisciplinary research team for its innovative and meritorious science that has advanced or likely will advance our fundamental knowledge of cancer or a team that has applied existing knowledge to advance the detection, diagnosis, prevention, or treatment of cancer.

The team selected to receive the Fifth Annual AACR Team Science Award will collectively be awarded a prize of $50,000 and be recognized during the AACR Annual Meeting 2011 in Orlando, FL, USA (April 2-6 2011). The representative institutions will be cited at the AACR Annual Meeting for their leadership role in fostering team science.

Eligibility Criteria

* For the purpose of this Award, a team is comprised of independent faculty-level researchers providing complementary interdisciplinary expertise, each of whom have made separate substantive and quantifiable contributions to the research being recognized.
* Team members may be working within the same institution or at several institutions; however, if researchers are in the same institution, they must have clearly separate funding and research space.
* The research to be recognized should reflect work towards a specific scientific goal that otherwise would not be realized by any single component of the team.
* Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry, or government.
* Teams comprising academic and industry researchers will be accepted.

Nomination Package

Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science (corresponding nominator). Any member of a team may serve as the corresponding nominator.

Nominations must be submitted electronically to https://proposalcentral.altum.com, no later than 4:00 p.m. United States Eastern Time on Thursday, September 30, 2010. Paper nominations will not be accepted.

A complete nomination package must consist of the following:

* the contact information of the corresponding nominator;
* a list of all members of the team, their professional titles and affiliations, with a description of each member's substantive and quantifiable contribution to the team;
* indication of the primary concentration of research area;
* 50-word summary statement of the research accomplishment or accomplishments for which the team is being nominated;
* a narrative, of no more than 3,000 words, describing in-depth the research accomplishment or accomplishments for which the team is being nominated as well as the significance and impact of the research, with no more than twelve (12) relevant publications referenced within the narrative;
* a list of the publications referenced with the research narrative, with full citations (no more than 12);
* a narrative, of no more than 1,000 words, describing the value-added activities of the team and the coordination of the research across the multiple performance sites;
* a descriptive list of institutional support of the team, such as pilot funding, technology transfer offices, shared resources, etc.; and
* original signatures of all team members.

Biosketch for each team member with relevant references, written in English; and

Letters of endorsement from Dean, Department Head, or Director of all institutions represented by the team members, confirming support for the nomination and certifying contents of nomination package, written in English.

The original signature page of the nomination form must contain the original signatures of all team members. Photocopies are not acceptable.

The original signature page must be sent via mail, with a postmark no later than three business days following the nomination deadline, to:

American Association for Cancer Research
AACR Team Science Award Selection Committee
615 Chestnut Street, 17th Floor
Philadelphia, PA 19106-4404

A nomination is not considered fully submitted until the corresponding nominator receives a confirmation e-mail from the AACR; confirmations will be sent within five business days.

Nomination Instructions

Will be available August 2010.

Selection

Nominations of teams will be considered by an Award Selection Committee of international cancer leaders appointed by the President of the AACR. After careful deliberations by the Award Selection Committee, their recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Selection of the Team Science Award winners will be made on the basis of the criteria listed above. No regard will be given to age, race, gender, nationality, geographic location, or religious or political views.

Questions?

Monique P. Eversley, Program Coordinator
+1 (267) 646-0576; awards@aacr.org

American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404

Conference Student Scholarships: Evolving Approaches to Early Stage Drug Discovery

Scholarship Deadline: December 2, 2010 (Midnight US Mountain Standard Time)

This meeting will cover multiple aspects of the challenges and opportunities facing drug discovery scientists. These challenges include: 1) diverse approaches to early stage discovery in a resource constrained environment, 2) evolution of preclinical drug discovery in academia, 3) evolution of drug leads/target validation from the NIH (MLPCN), 4) funding early stage/risky programs, 5) external licensing of programs and 6) advances in biomarkers/imaging to enable target selection and rapid go/no go decisions. The meeting goals are to bring together experts in all of these areas, present findings/opinions and initiate dialog on these topics. This would be the first meeting to bring together drug discovery scientists form big Pharma, biotech, academia, the MLPCN and Foundations – each with unique missions and approaches and share their respective experiences.

Keystone Symposia is offering scholarships to students and post-docs this conference season. These scholarships, of up to $1000 each, are to be used to help defray the expenses associated with conference attendance, including air (on a U.S. air carrier), ground transportation and lodging costs. Receipts will be required to receive reimbursement.

Abstracts submitted for poster presentation will be used as the basis for awarding the scholarships. Conference organizers will select the scholarship recipients based on the quality of science of the abstract and the relevance of the abstract to the conference topic. Only one application per abstract is accepted.

Keystone Symposia
221 Summit Place #272
PO Box 1630
Silverthorne, CO 80498
www.keystonesymposia.org

Financial Assistance / Student Scholarships
Phone: +1 (800) 253-0685 or
Ksenia Shambarger - +1 (970) 262-1230 extension 140
Fax: +1 (970) 262-0311

Request for Proposals: Novel Approaches to Drug Discovery for Alzheimer’s Disease

ADDF funds drug discovery research programs from domestic and international investigators in academia and biotechnology companies. In addition, ADDF initiates, sponsors, and co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation, bringing together physicians, scientists, and policy makers worldwide.

As a biomedical venture philanthropy, ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development. We fund high risk, early stage drug discovery and development projects and catalyze scientists to enter the drug discovery field. We have adapted the operating model and principles of venture capital investing to our philanthropic mission in biomedical research. We help to create new biotechnology companies, and to fund early stage biotechnology companies, with programs dedicated to Alzheimer’s disease drug discovery. We seek a return on investment for all of our grants based on the achievement of scientific milestones. When these milestones are met, funds return to the Foundation to increase our ability to support more research.

ADDF FUNDING PROGRAMS
• ADDF Academic Drug Discovery and Development Program seeks to create and support innovative translational programs for Alzheimer’s disease, related dementias and cognitive aging in academic medical centers and universities. Biomarker development studies and innovative proof of concept pilot clinical trials of new approaches to treatment, prevention and early detection are also supported.

• ADDF Biotechnology Development Program supports qualified scientific projects in existing, private, early-stage biotechnology companies. ADDF will provide support for qualified projects in more advanced companies if a clear need for non-profit funding to support the project can be demonstrated and justified.

• ADDF Biotechnology Founders Technology Transfer Program supports academic programs that are eligible for technology transfer and the start-up of new biotechnology companies. Up to 35% of funds from these awards may be employed for expenses related to company formation, such as administrative, legal, patent and third-party vendor costs.

RESEARCH FUNDING PRIORITIES
• Treatment of Alzheimer’s disease and cognitive aging: ADDF supports drug discovery and drug development efforts towards novel treatments for Alzheimer’s disease and related dementias, and cognitive decline associated with aging. These may include disease modifying agents for preventing or delaying progression as well as cognitive enhancers. ADDF provides funding for target validation and proof-of-concept studies, high throughput screening of chemical libraries, lead discovery and optimization, rational medicinal chemistry, and pre-clinical drug development. ADDF also supports small proof-of principle clinical research studies.

• Early detection and prevention: ADDF supports the development of biomarkers, such as advanced brain imaging technologies, CSF and blood tests for the early detection of mild cognitive impairment, Alzheimer’s disease and related dementias. ADDF also supports clinical research projects to improve early detection of cognitive impairment through population-based approaches that can impact large numbers of individuals at risk.

GENERAL SUBMISSION GUIDELINES
Grant applications are usually solicited by private invitation. Unsolicited proposals are also accepted, but inquiries with ADDF staff are encouraged to determine the Foundation’s interest prior to application. ADDF provides support for 1 year of research with potential for future follow-on funding. We seek successful long-term partnerships with investigators and research organizations.

APPLICATION PROCEDURE
Full application guidelines and further information can be found on our website (www.alzdiscovery.org). All applicants are required to complete an electronic "Letter of Intent" (LOI) available on our website. After review of the LOI, we may invite a full application via email with a link to the electronic application form. ADDF will attempt to make a determination of interest within 90 days of receipt of the application.

ADDF accepts grant applications for the “General Request for Proposals” research award programs throughout the year (2010 deadlines for full proposals are January 7, April 1, July 1, and October 1).

If you would like to contact the Foundation, please call (212) 935-2402, or contact us by regular mail at the following address:

Alzheimer’s Drug Discovery Foundation
1414 Avenue of the Americas, Suite 1502
New York, NY 10019

Promega Biotechnology Research Award

Honors outstanding contributions to the application of biotechnology through fundamental microbiological research and development.

Eligibility:
A nomination can be a single exceptionally significant achievement or the aggregate of a number of exemplary achievements.

Award:
A cash prize of $5,000, a commemorative piece, and travel to the ASM General Meeting where the laureate delivers the Promega Biotechnology Research Award Lecture.

Deadline: October 1.

Nominations:
Nominations will be considered without updating for three years. Self-nominations, co-nominations, and more than one nomination per nominee will not be accepted. Only one nominating form and two supporting forms are accepted per nomination. The two supporters must be persons other than the nominator who are familiar with the nominee's qualifications and accomplishments. Only one of the three individuals involved in the nomination may be employed at the nominee's institution. The nominator and supporters must not share employers. Nominations must consist of the following:

* Curriculum vitae, including a list of publications, emailed to awards@asmusa.org
* Nominating form
* Supporting form

ASM Awards are granted at the discretion of award selection committees and may not be awarded every year.

Sponsor: Promega Corporation

American Society for Microbiology
1752 N Street, N.W.
Washington, D.C. 20036-2904
(202) 737-3600